The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom
Vaccination of the eligible population would contribute to significant reductions in hospitalizations, deaths, and long COVID in the UK in the 2024-2025 season. Expanding the target population continues to be cost-effective. Use of the Moderna Autumn 2024 Campaign is predicted to reduce SARS-CoV-2 infections and associated outcomes in a cost-effective manner and will contribute to a more resilient healthcare system in the UK.
Authors
- Nicolas Van de Velde (ORCID: https://orcid.org/0000-0003-4358-5873)
- Orsolya Balogh (ORCID: https://orcid.org/0000-0003-0939-2859)
- Stuart Carroll (ORCID: https://orcid.org/0000-0002-1237-0370)
- Keya Joshi (ORCID: https://orcid.org/0000-0003-0244-0459)
- Michael Maschio (ORCID: https://orcid.org/0000-0002-6595-3019)
- Ekkehard Beck
- Michele Kohli (ORCID: https://orcid.org/0000-0002-6032-9356)
- Amy Lee
Institutions
- STR Biotech (South Korea) (KR)
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1080/13696998.2024.2413288
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95